Asthma drug roflumilast tested for Long-Term safety in new study
NCT ID NCT00246922
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the long-term safety of the drug roflumilast in adults with asthma. Participants had already finished a 24-week study and took the drug once daily for another 28 weeks. The goal was to see if the drug remained safe over a longer period.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIAL ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nycomed Japan and Mitsubishi Tanabe Pharma Corporation
Osaka, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could vitamin d levels influence asthma control?
- Could a chromium supplement help obese adults breathe easier?
- Can acupuncture stop an asthma attack? new study investigates
- Golfers test N95 masks to breathe easy in wildfire smoke
- Massive study reveals hidden dangers of common steroid treatments
- Breath prints may reveal lung disease secrets without needles